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The interleukin-1 (IL-1) family of cytokines consists of struc-
turally and functionally related molecules with pleiotropic activi-
ties involved in immune and inflammatory responses (Dinarello,
1996). IL-1b, one member of this family, has been implicated in a
wide range of physiological and pathological processes, including
mitogenic T-cell stimulation, wound healing, cellular adhesion,
cytokine production, inflammation and sepsis (Oppenheim et al,
1986; Dinarello and Thompson, 1991; Dinarello and Wolff, 1993).
Other members of this family include IL-1a and a naturally occur-
ring antagonist, referred to as IL-1 receptor antagonist (IL-1ra),
which share sequence homologies and the usage of similar
receptors (Dinarello and Thompson, 1991). IL-1b is intracellularly
cleaved and exported in large quantities after the stimulation of its
producer cell, whereas IL-1a is synthesized in much lower quanti-
ties and does not appear to be actively secreted (Hazuda et al,
1988; Grassi et al, 1991). IL-1ra is now known to exist in two
forms, a secretory product (sIL-1ra) and an intracellular molecule
(icIL-1ra) found in the cytoplasm (Dinarello, 1996). Both forms of
IL-1ra are encoded from the same gene but their transcription is
regulated by different promoter regions.
IL-1b is synthesized as an inactive 33 kDa precursor protein
(pIL-1b) that is cleaved by a protease to generate the mature 17-
kDa secretory protein (mIL-1b) (Kostura et al, 1989; Lonnenmann
et al, 1989). A cystein protease responsible for the cleavage of IL-
1b has been identified and termed IL-1b converting enzyme (ICE)
(Black et al, 1989; Cerretti et al, 1992). Several enzymes sharing
sequence homology and the ability to cleave proteins at an
asparagine-site have been identified over the past few years and
were recently named caspases (Alnemri et al, 1996). Besides ICE,
which was assigned to the name caspase-1, nine other caspases are
known, several of which are known to be involved in the regula-
tion of apoptosis. However, it has recently been shown that ICE
does not play a requisite role in Fas-mediated apoptosis, and thus
the role of ICE during apoptosis remains unclarified (Enari et al,
1996; Tatsuda et al, 1996; Smith et al, 1997).
IL-1 regulates the proliferation of many cell types both in a posi-
tive and in a negative manner. IL-1 stimulates the growth of thymo-
cytes, B-cells, fibroblasts and a human glioma cell line (Gery et al,
1972; Schmidt et al, 1982; Lachman et al, 1987; Freedman et al,
1988). In contrast, IL-1 is antiproliferative for a human melanoma
cell line (Onozaki et al, 1985), several malignant human mammary
cell lines (Gaffney and Tsai, 1986) and human endothelial cells
(Maier et al, 1990). Surprisingly, several authors have reported that
endogenous IL-1b regulates both cell proliferation and cell death in
some cell lines (Fratelli et al, 1995; Friedlander et al, 1996). The
mechanism underlying the sensitivity to IL-1 has only been
partially clarified. Araki et al (1994) reported that resistance to the
antiproliferative effect of IL-1 is associated with endogenous IL-1
production. Friedlander et al (1996) reported that the ICE down-
regulates IL-1b-IL-1 receptor-binding activity, which causes the
resistance to IL-1b. Furthermore, many authors have recently
reported that endogenous IL-1 and IL-1ra balance regulates cell
proliferation in many cell types (Corradi et al, 1995; Furukawa et
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this balance can be regulated in these cells. Thus, both IL-1ra and
ICE seem to be closely associated with IL-1-mediated cell prolifer-
ation and/or cell death.
We have previously reported that the bladder cancer cell line
KU-19-19 produces multiple cytokines; IL-6, IL-8, granulocyte-
colony stimulating factor (G-CSF) and granulocyte–macrophage
colony stimulating factor (GM-CSF) (Tachibana et al, 1997a).
IL-1 is well known as one of the key cytokines that can promote
the production of these cytokines (Dinarello, 1996). In cancer cells
such as KU-19-19, that produce multiple cytokines regulated by
IL-1, it is thought that IL-1 plays a crucial role in both the produc-
tion of various cytokines and cell proliferation.
In the present study, we hypothesized that endogenous IL-1b
and IL-1ra balance could regulate the ICE expression. We demon-
strated that the gene expressions of both ICE and IL-1ra were
suppressed and IL-1b secretion was inhibited in IL-1b-resistant
cancer cell lines. Furthermore, we demonstrated that the over-
expression of sIL-1ra could enhance ICE gene expression, which
induced the cleavage and secretion of intracellular pIL-1b and
promoted IL-1b-mediated cell death, while exogenous IL-1ra
could not enhance it. These findings may provide the key clues to
clarify the interaction of endogenous IL-1b, IL-1ra and ICE.
MATERIALS AND METHODS
Reagents
Recombinant human IL-1b (specific activity; 1 ´ 109 units per mg)
was purchased from Genzyme (Boston, MA, USA) and recombi-
nant human IL-1ra (specific activity; 5 ´ 105 units per mg) was
purchased from Anapure Bioscientific Co. Ltd (Beijing, China).
Rabbit anti-human IL-1b monoclonal antibody and rabbit anti-
human IL-1ra antibody were purchased from Genzyme. Acetyl-
Tyr-Val-Ala-Asp-CHO (YVAD-CHO) was obtained from Sigma
(St Louis, MO, USA).
Recombinant adenovirus vectors
We constructed a recombinant adenovirus vector expressing sIL-1ra
(Adex1CAKTIL-1ra; abbr.: AxIL-1ra). A modification of method
(COS-TPC method) developed by Dr Saito et al (Miyake et al, 1996),
was used to construct this adenovirus vector. In brief, this replication-
deficient adenovirus is based on adenovirus type 5 which lacks the
E1A, E1B and E3 regions of the virus and contains the CAG
promoter, sIL-1ra cDNA, and poly-adenosine (poly-A) signal
sequences inserted into the E1-deleted region. The sIL-1ra cDNA,
amplified by RT-PCR using the total RNA obtained from U937 cells
stimulated by 10 ng ml–1 TPA for 20 h and the oligo-dT primer and
the following primers, 5¢- GCCACCATGGAAATCTGCAGAG-
GCCTCCGCAGTC-3¢ and 5¢-GCTCTAGACTACTCGTCCTC-
CTGGAAGTAGAATTTGG-3¢, was end-blunted with T4 DNA
polymerase, digested with XbaI, cloned into Sca I-Xba I site of pBK-
CMV, and sequenced. The Hind III-Sma I fragment of the cDNA was
inserted into the unique Swa I site of adenovirus genome in the
cassette cosmid, pAdex1CA1wt. The cosmid bearing the expression
unit in adenovirus genome was then co-transfected into human
embryonic kidney 293 cells together with the adenovirus
DNA–terminal protein complex (DNA-TPC) digested at seven sites
with EcoT22 I. Purified virus stocks were prepared by CsCl step
gradient centrifugation as previously described method (Kanegae
et al, 1994). As a control vector, recombinant lacZ adenovirus
(Adex1CALacZ; abbr.: AxLacZ), containing the CAG promoter,
lacZ gene, and poly-A signal sequences, was kindly supplied by Dr
Saito et al (Kanegae et al, 1995). Almost all of the cancer cells
infected with AxLacZ at 5 MOI demonstrated lacZ expression (data
not shown).
Cell culture
Four different urological cancer cell lines derived from human
bladder cancer cells: KU-19-19 and KU-1 (Tachibana, 1982;
Tachibana et al, 1997b), and human renal cancer cells: KU-2
(Katsuoka et al, 1976) and KU-19-20 were used. KU-19-19
(Tachibana et al, 1995, 1997a, 1997b) has recently been established
from the advanced bladder cancer patient and KU-19-20 (unpub-
lished data) has also recently been established from the advanced
renal cell carcinoma patient. These two patients had marked leuco-
cytosis. We have found that both KU-19-19 and KU-19-20 produce
multiple cytokines, IL-6, IL-8, G-CSF and GM-CSF. Furthermore,
G-CSF induces autocrine growth on KU-19-19 (Tachibana et al,
1995) and GM-CSF induces autocrine growth on KU-19-20
(unpublished data), while neither KU-1 nor KU-2 produces
multiple cytokines. These cancer cell lines were routinely propa-
gated in a monolayer culture in a humidified incubator at 37°C in
a 5% carbon dioxide/95% air atmosphere. Cells were grown in
RPMI-1640 medium supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 100 mg ml–1 streptomycin (Gibco-BRL,
Grand Island, NY, USA) and 100 IU ml–1 penicillin (Gibco-BRL).
Western blot analysis
Cells (1 ´ 106) were homogenized in 100 ml of lysis buffer (20 mM
Tris–HCl pH 8.0, 137 mM sodium chloride, 10% glycerol, 1% NP-
40, 1 mM phenylmethylsulphonyl fluoride (PMSF; Sigma)), incu-
bated at 4°C for 20 min, and then were centrifuged at 10 000 g for
15 min at 4°C to remove debris. The protein concentrations in the
cell lysates were determined by the use of bicinconinic acid (BCA)
protein assay reagent (Pierce, Rockford, IL, USA), and then the
lysates were mixed with sample buffer containing 2-mercaptoethanol
and boiled for 5 min. Samples containing 30 mg total protein were
subjected to sodium dodecyl sulphate polyacrylamide gel electro-
phoresis (SDS-PAGE) using a 14% polyacrylamide gel (Multigel,
Daiichi Pure Chemicals, Tokyo, Japan), and then were transferred
onto a polyvinylidene difluoride (PVDF) membrane (Immobilon,
Daiichi Pure Chemicals, Tokyo, Japan) by semi-dry electroblotting.
The membrane was blocked for 2 h at 37°C in phosphate-buffered
saline (PBS) with 0.05% Tween-20 (PBT), containing 1% bovine
serum albumin (BSA). Either rabbit anti-IL-1b monoclonal antibody
or anti-IL-1ra antibody was added at a concentration of 10 mg ml–1
and incubated for 2 h at 37°C. Immunoreactive polypeptides were
detected by using donkey anti-rabbit immunoglobulin G conjugated
to horseradish peroxidase in an enhanced chemiluminescence system
according to the manufacturer’s protocol (Amersham Pharmacia
Biotech, Buckinghamshire, UK).
Northern blot analysis
The total RNA from each cancer cell was isolated by acid–guani-
dinium–thiocyanate–phenol–choloroform extraction. The concen-
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260 nm. The total RNA samples (20 mg) were size-fractioned by
electrophoresis in 1% formaldehyde agarose gel. The RNA was
transferred overnight to nylon filters (Hybond-N; Amersham) by
capillary diffusion in 20 ´ SSC (1 ´ SSC is 0.15 mol sodium chlo-
ride (NaCl) and 0.015 mol sodium citrate 1–1) and then baked at
80°C in a vacuum for 2 h. The 30-mer antisense oligonucleotide
probes for IL-1b (nucleotide numbers 787–816), IL-1ra
(nucleotide numbers 342–371) and ICE (nucleotide numbers
664–693) were 3’-end labelled with [a32P] dCTP (6000 Ci mmol–1;
Amersham) using terminal transferase (Terminal Transferase 500
U; Boehringer Mannheim, Germany) and purified through a
Sephadex G50 NICTM Column (Pharmacia Biotech, Uppsala,
Sweden). The filters were prehybridized at 65°C for 1–2 h in
hybridization buffer containing 10% dextran sulphate, 1 M NaCl,
25 mg yeast torula RNA ml–1 (Boehringer Mannheim) and 1%
SDS, and then were hybridized overnight at 65°C with 2 ´ 106 ct
min–1 labelled probes ml–1. A 27-mer antisense oligonucleotide
probe for human b-actin was used as a loading control (Toyobo,
Tokyo, Japan). The hybridized filters were washed three times for
20 min at 60°C in 0.1 ´ SSC with 0.1% SDS. Thereafter, the filters
were subjected to autoradiography.
Cell growth assay
Cells were incubated in a flat-bottom 96-well plate (Falcon;
Becton Dickinson Labware, Lincoln Park, NJ, USA) for different
time periods. At the end of the experiment, 20 ml of the dye MTT
(3,(4,5-dimethylthiazol-2-y1-) diphenyltetrazolium bromide 5 mg
ml–1) was added to each well and the plates were incubated for 3 h
at 37°C. Then, 100 ml of lysis buffer (20% SDS in 50% N,N-
dimethylformamide, containing 0.5% [v:v] 80% acetic acid and
0.4% [v:v] 1 N hydrochoric acid were added to each well and the
colour intensity (proportional to the number of live cells) was
assessed using a microplate reader at 570 nm wavelength. Each
experiment was performed in triplicate.
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Table 1 The concentrations of several cytokines in the supernatants of cancer cells
IL-1b IL-1ra IL-1ra/IL-1b ratio IL-6 IL-8 G-CSF GM-CSF
KU-19-19 27.2 ± 5.1 84.5 ± 10.1 3.1 64.9 ± 14.1 487.5 ± 32.8 519.7 ± 58.3 191.8 ± 29.0
KU-1 52.4 ± 9.4 726.7 ± 64.1 13.9 0.5 ± 0.1 ND ND ND
KU-2 79.3 ± 8.6 854.9 ± 43.6 10.7 0.7 ± 0.1 ND ND ND
KU-19-20 15.6 ± 4.6 74.6 ± 11.5 4.8 91.3 ± 12.4 395.7 ± 44.7 181.0 ± 21.4 398.3 ± 61.1
(pg ml–1)
Cells (1 ´ 104 per well) were incubated in a 1-ml culture medium for 48 h and the concentrations of several cytokines in the supernatants were measured by
ELISA. The concentrations of both IL-1b and sIL-1ra in the supernatants and IL-1ra/IL-1b ratios were higher in KU-1 and KU-2 than in KU-19-19 and KU-19-20.
On the other hand, IL-6, IL-8, G-CSF and GM-CSF were secreted in large quantities in both KU-19-19 and KU-19-20, but not in either KU-1 or KU-2. The results
are expressed as the mean ± s.d. of triplicate samples. ND, not detectable. The experiments were repeated three times with similar results.
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Figure 1 The levels of gene expression and production of IL-1b, IL-1ra and ICE in four cancer cells. (A) Detection of gene expression by Northern blot
analysis. Cells were incubated for 48 h and total RNA samples (20 mg) were size-fractioned by electrophoresis in 1% formaldehyde agarose gel. The RNA was
transferred and hybridized by the 30-mer antisense oligonucleotide probes for IL-1b, IL-1ra and ICE as described in Materials and Methods. A 27-mer antisense
oligonucleotide probe for human b-actin was used as a loading control. IL-1b gene was expressed at the same levels in all cancer cells. In contrast, the levels of
IL-1ra and ICE gene expression were suppressed more in KU-19-19 (lane 1) and KU-19-20 (lane 4) than in KU-1 (lane 2) and KU-2 (lane 3). (B) Detection of
intracellular IL-1b and IL-1ra by Western blot analysis. Cells were incubated for 48 h and cells (1 ´ 106) were lysed and 30 mg of each lysate was subjected to
SDS-PAGE, transferred onto a polyvinylidene difluoride membrane, and immunoblotted with rabbit anti-IL-1b antibody or anti-IL-1ra antibody and donkey anti-
rabbit immunoglobulin G conjugated to horseradish peroxidase as described in Materials and Methods. The intracellular form of IL-1ra (icIL-1ra, about 20 kDa)
was detected in all cancer cells. In KU-19-19 (lane 1) and KU-19-20 (lane 4), the bands corresponding to immature form pIL-1b (about 33 kDa) were strongly
detected, while smaller bands were detected in KU-1 (lane 2) and KU-2 (lane 3). These blots are representative samples of two experiments showing similar
tendenciesDetermination of the concentrations of IL-1b and
several cytokines by ELISA
Cells (1 ´ 104 per well) were incubated in a 1 ml culture medium
for different time periods. Following incubation, each cell culture
was centrifuged and the concentrations of IL-1b, IL-1ra, IL-6, IL-
8, G-CSF and GM-CSF in the supernatants were measured by
enzyme-linked immunosorbent assay (ELISA). Each experiment
was performed in triplicate.
Fragmented DNA detection by ELISA
The presence of fragmented DNA was assayed by specific two-site
ELISA employing anti-histone as the primary antibody and anti-
DNA as the secondary antibody according to the manufacturer’s
instructions (Boehringer Mannheim, TerreHoite, CA, USA). Cells
were incubated for different times periods and cells (1 ´ 104 cells
ml–1) were transferred into sterile 1.5-ml microcentrifuge tubes.
Cells were then spun, resuspended in 500 ml of lysis buffer and
incubated for 30 min on ice. After centrifugation, the supernatants
(cytosol-containing low molecular weight, fragmented DNA) were
diluted 1:10 (v:v) with incubation buffer and 100 ml of the solution
(1 ´ 103 cell equivalents per ml) pipetted into the wells of a 96-well
plate precoated with anti-histone antibody. After incubation and
washing, the secondary antibody (anti-DNA) conjugated with
horseradish peroxidase was added to the wells. At the end of an
additional period of incubation, the wells were treated with chro-
mogen substrate and the intensity of the colour development was
assayed with an ELISA plate reader at a 405/490 nm wavelength.
Each experiment was performed in triplicate.
Statistical analysis
The unpaired t-test was used to determine the statistical differ-
ences. A P-value of less than 0.05 was designated to be statisti-
cally significant.
RESULTS
The levels of gene expression and secretion of
cytokines in the cancer cells
Cells were incubated for 48 h and the gene expressions of IL-1b, IL-
1ra and ICE were assessed by Northern blot analysis. IL-1b gene
was expressed at the same levels in all cancer cells. In contrast, the
gene expressions of IL-1ra and ICE in KU-19-19 and KU-19-20
were suppressed compared with those in KU-1 and KU-2 (Figure
1A). Western blot analysis showed that the icIL-1ra (about 20 kDa)
was detected at the same levels in all cancer cells. The bands corre-
sponding to immature form pIL-1b (about 33 kDa) were strongly
detected in KU-19-19 and KU-19-20, whereas smaller bands were
detected in KU-1 and KU-2 (Figure 1B). ELISA showed that the
concentrations of both IL-1b and sIL-1ra in the supernatants and IL-
1ra/IL-1b ratios were higher in KU-1 and KU-2 than in KU-19-19
and KU-19-20. On the other hand, IL-6, IL-8, G-CSF and GM-CSF
were secreted in large quantities in both KU-19-19 and KU-19-20,
but not in either KU-1 or KU-2 (Table 1).
Effect of exogenous IL-1b on the cell growth and
cytokine secretion
The cancer cells (1 ´ 103 per well) were treated with 10 ng ml–1 IL-
1b and incubated for 48 h and then the effect of exogenous IL-1b on
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Figure 2 Effect of exogenous IL-1b on cell survival and cytokine secretion. (A) The cancer cells (1 ´ 103 per well) were treated with 10 ng/ml IL-1b and
incubated for 48 h and the effect of exogenous IL-1b on the growth of these cancer cells was examined by MTT assay. IL-1b treatment stimulated cell growth in
both KU-19-19 and KU-19-20 (P < 0.05), while it induced a dramatic growth inhibition in KU-1 and KU-2 (P < 0.01). (B) KU-19-19 and KU-19-20 cells (1 ´ 104
per well) were treated with 10 ng ml–1 IL-1b and incubated for 48 h and the levels of several cytokines in the supernatants were measured by ELISA. The levels
of cytokines in the supernatants were elevated significantly more in both KU-19-19 and KU-19-20 than in the non-treated controls (P < 0.01). The results are
expressed as the relative ratio to the non-treated controls. Bars, s.d. of triplicate samples. The experiments were repeated three times with similar resultsthe growth of these cancer cells was examined by MTT assay. As
shown in Figure 2A, IL-1b treatment stimulated cell growth in both
KU-19-19 and KU-19-20 significantly compared with non-treated
controls (P < 0.05), while it induced a dramatic growth inhibition in
KU-1 and KU-2 (P < 0.01). Furthermore, KU-19-19 and KU-19-20
(1 ´ 104 per well) were treated with 10 ng ml–1 IL-1b and incubated
for 48 h and the levels of several cytokines in the supernatants were
measured by ELISA. The levels of cytokines in the supernatants
were elevated significantly more in both KU-19-19 and KU-19-20
than in the non-treated controls (P < 0.01, Figure 2B).
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Figure 3 ICE is required for IL-1b-induced cell death in KU-1 and KU-2. KU-1 and KU-2 cells (1 ´ 103 per well), treated with 10 ng ml–1 IL-1b and various
concentrations of YVAD-CHO, a reversible ICE inhibitor, were incubated for different time periods and the cell growth was estimated by MTT assay. YVAD-CHO
treatment blocked IL-1b-induced growth inhibition dose-dependently in both KU-1 and KU-2. The results are expressed as the relative ratio to the non-treated
controls. Bars, s.d. of triplicate samples. The experiments were repeated three times with similar results
Figure 4 Effect of AxIL-1ra on ICE gene expression and IL-1b secretion in KU-19-19 and KU-19-20. Cells (1 ´ 104 per well), treated with AxIL-1ra at a
concentration of 5 MOI, were incubated for different time periods and the levels of IL-1ra and IL-1b in the supernatants were examined by ELISA. Furthermore,
the levels of IL-1b, IL-1ra and ICE gene expression were examined by Northern blot analysis. The IL-1ra gene overexpression was detected 12 h later in KU-19-
19 and 18 h later in KU-19-20. The level of IL-1b gene expression did not change in either KU-19-19 or KU-19-20. The ICE gene expression was, however,
enhanced according to the IL-1ra gene overexpression. Furthermore, the concentrations of IL-1b as well as IL-1ra in the supernatants dramatically increased
after the strong gene expressions of IL-1ra and ICE in both KU-19-19 and KU-19-20. The results of ELISA are expressed as the mean ± s.d. of triplicate
samples. Bars, s.d. The experiments were repeated twice with similar results
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We investigated whether or not ICE is required for IL-1b-induced
growth inhibition using an ICE inhibitor YVAD-CHO. KU-1 and
KU-2 cells (1 ´ 103 per well), treated with 10 ng ml–1 IL-1b and
various concentrations of YVAD-CHO, were incubated for different
time periods and cell survival was estimated by MTT assay. YVAD-
CHO treatment blocked IL-1b-induced growth inhibition in a dose-
dependent fashion in both KU-1 and KU-2 (Figure 3).
Effect of AxIL-1ra on ICE gene expression and IL-1b
secretion in KU-19-19 and KU-19-20
The results of Figure 1 and Table 1 suggested that the IL-1ra
expression might regulate the ICE expression. We therefore inves-
tigated whether endogenous sIL-1ra overexpression could enhance
the ICE gene expression in KU-19-19 and KU-19-20. Cells, treated
with AxIL-1ra at a concentration of 5 multiplicity of infection
(MOI), were incubated for different time periods and the gene
expressions of IL-1b, IL-1ra and ICE were examined by Northern
blot analysis. Furthermore, the levels of IL-1ra and IL-1b secretion
in the supernatants were examined by ELISA. The IL-1ra gene
overexpression was detected 12 h later in KU-19-19 and 18 h later
in KU-19-20. The ICE gene expression was enhanced according to
the IL-1ra gene overexpression. Furthermore, the concentrations of
IL-1b as well as IL-1ra in the supernatants dramatically increased
after the overexpression of IL-1ra and ICE in both KU-19-19 and
KU-19-20, whereas the level of IL-1b gene expression did not
change in either cell lines (Figure 4). AxLacZ treatment did not
change the levels of either the ICE gene expression or IL-1b secre-
tion (data not shown). Although the ICE gene expression was also
enhanced in KU-1 and KU-2 treated with AxIL-1ra, the concentra-
tion of IL-1b did not dramatically increase (data not shown).
Effect of AxIL-1ra on the cell growth and the secretion
of several cytokines
We investigated whether AxIL-1ra treatment could have some
effect on the growth of the cancer cells. The cancer cells (1 ´ 103
per well), treated with various concentrations of AxIL-1ra were
incubated for 48 h and the cell growth was examined by MTT
assay. As shown in Figure 5A, AxIL-1ra-treated cells showed
significant growth inhibition on both KU-19-19 and KU-19-20 in
dose-dependent fashion compared with AxLacZ-treated control
cells (P < 0.05). On the other hand, neither KU-1 nor KU-2 treated
with AxIL-1ra showed significant growth inhibition compared
with AxLacZ-treated control cells. Furthermore, KU-19-19 and
KU-19-20 cells (1 ´ 104 per well), treated with 5 MOI of AxIL-1ra
or AxLacZ, were incubated for 48 h and the levels of several
cytokines in the supernatants were measured by ELISA. The rela-
tive values of their concentrations in the supernatants in the AxIL-
1ra-treated cells (MOI = 5) decreased significantly compared with
those in the AxLacZ-treated controls in both KU-19-19 and KU-
19-20 (P < 0.01, Figure 5B). On the other hand, the concentration
of IL-1b was more than 100-fold elevated in both cell lines (data
not shown).
Exogenous IL-1ra can not induce either ICE gene
expression or growth inhibition, while it can block the
secretion of cytokines in KU-19-19 and KU-19-20
Considering the possibility that the surplus amount of extracellular
sIL-1ra derived from AxIL-1ra might promote ICE gene expres-
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Figure 5 Effect of AxIL-1ra on the cell growth and cytokine secretion. (A) The cancer cells (1 ´ 103 per well), treated with various concentrations of AxIL-1ra or
AxLacZ were incubated for 48 h and cell survival was examined by MTT assay. AxIL-1ra-treated cells showed significant growth inhibition on both KU-19-19 and
KU-19-20 in dose-dependent fashion compared with AxLacZ-treated control cells. On the other hand, neither KU-1 nor KU-2 treated AxIL-1ra showed significant
cell damage compared with AxLacZ-treated control cells. (B) KU-19-19 and KU-19-20 cells (1 ´ 104 per well), treated with 5 MOI of AxIL-1ra or AxLacZ, were
incubated for 48 h and the levels of several cytokines in the supernatants were measured by ELISA. The relative values of the concentrations of several
cytokines in the supernatants in AxIL-1ra-treated cells (MOI = 5) decreased significantly compared with those in the AxLacZ-treated controls in both KU-19-19
and KU-19-20. The results are expressed as the relative ratio to the AxLacZ-treated controls. Bars, s.d. of triplicate samples. The experiments were repeated
three times with similar resultssion and inhibit cell growth, we investigated whether exogenous
IL-1ra could regulate ICE gene expression and cell growth in KU-
19-19 and KU-19-20. Cells (1 ´ 103 per well), treated with various
concentrations of IL-1ra, were incubated for 48 h and cell growth
was examined by MTT assay. Furthermore, the level of ICE gene
expression was examined by Northern blot analysis. As shown in
Figure 6A, IL-1ra at the concentrations of 100 ng ml–1 or less had
no effect on the cell growth of either KU-19-19 or KU-19-20. In
addition, IL-1ra treatment was not able to enhance the ICE gene
expression in either KU-19-19 or KU-19-20 (Figure 6B). On the
other hand, ELISA study showed IL-1ra treatment (100 ng ml–1)
inhibited the secretion of several cytokines significantly in both
KU-19-19 and KU-19-20 compared with non-treatment 48 h later
(P < 0.01), while it had little effect on the concentration of IL-1b
(Figure 6C). These results suggested that AxIL-1ra-induced ICE
expression, IL-1b secretion and growth inhibition did not result
from extracellular sIL-1ra and that the decrease of the concentra-
tions of several cytokines but IL-1b had little effect on the cell
growth in either KU-19-19 or KU-19-20 during the observation
period.
AxIL-1ra induces apoptotic cell death on both KU-19-19
and KU-19-20
We furthermore investigated whether AxIL-1ra-induced growth
inhibition could result from apoptotic cell death in KU-19-19 and
KU-19-20 by fragmented DNA ELISA. In KU-19-19, absorbance
was elevated significantly more in the AxIL-1ra (MOI = 5)-treated
cells than in the AxLacZ (MOI = 5)-treated cells 24 h later and it
was dramatically elevated 48 h later (P < 0.01), indicating the
presence of the low molecular weight fragmented DNA in the
cytosolic compartment. In KU-19-20, it was also significantly
elevated 48 h later (P < 0.01, Figure 7).
Both IL-1b and ICE are required for AxIL-1ra-induced
cell death in KU-19-19 and KU-19-20
We investigated whether both IL-1b and ICE are required to induce
growth inhibition on KU-19-19 and KU-19-20. AxIL-1ra (MOI =
5)-infected cells (1 ´ 103 per well) were treated with either IL-1ra
(100 ng ml–1), anti-IL-1b antibody (10 mg ml–1) or YVAD-CHO
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Figure 6 Effect of exogenous IL-1ra on the cell growth, ICE gene expression and cytokine secretion in KU-19-19 and KU-19-20. (A) Cells (1 ´ 103 per well),
treated with various concentrations of IL-1ra were incubated for 48 h and cell survival was estimated by MTT assay. IL-1ra at the concentrations of 100 ng ml–1
or less had no effect of the cell growth in either KU-19-19 or KU-19-20. The results are expressed as the relative ratio to the non-treated controls. Bars, s.d. of
triplicate samples. (B) The level of ICE gene expression by exogenous IL-1ra treatment. Northern blot analysis showed that IL-1ra treatment (100 ng ml–1) or
less could not enhance the ICE gene expression in either KU-19-19 or KU-19-20. (C) Cells (1 ´ 104 per well), treated with various concentrations of IL-1ra were
incubated for 48 h and the levels of several cytokines in the supernatants were measured by ELISA. In both KU-19-19 and KU-19-20, IL-1ra treatment
(100 ng ml–1) significantly inhibited the secretion of several cytokines but IL-1b compared with non-treatment. The results are expressed as the relative ratio to
the non-treated controls. Bars, s.d. of triplicate samples. The experiments were repeated twice with similar results(20 mM), and then were incubated for 48 h, and the cell growth was
estimated by MTT assay. Both IL-1ra and anti-IL-1b antibody were
used as the inhibitors of IL-1b in the supernatants and YVAD-CHO
as an inhibitor of ICE. They significantly blocked AxIL-1ra-
induced growth inhibition in both KU-19-19 and KU-19-20
(P < 0.05). Furthermore, IL-1b (10 ng ml–1) could further enhance
AxIL-1ra-induced growth inhibition in both KU-19-19 and KU-19-
20 (P < 0.05), while it induced growth promotion under AxLacZ
treatment (Figure 8). YVAD-CHO (20 mM or less) only did not
effect the cell growth in either KU-19-19 or KU-19-20 (data not
shown).
DISCUSSION
Many authors have reported that cell resistance to the antiprolifera-
tive effect of IL-1 appears to constitutively produce IL-1, which may
be associated with cell proliferation including autocrine/paracrine
growth and thus promote the production of other cytokines (Onozaki
et al, 1985; Ito et al, 1993; Araki et al, 1994; Fratelli et al, 1995;
Furukawa et al, 1995). In the present study, we first investigated
whether or not IL-1b-producing cells are really resistant to IL-1b. We
demonstrated that IL-1b-sensitive cancer cell lines, KU-1 and KU-2,
produce IL-1b. Surprisingly, the IL-1b concentrations in the super-
natants were rather lower in IL-1b-sensitive cancer cell lines. This
finding indicates that endogenously IL-1b producing cells are thus
not necessarily resistant to IL-1b.
We next investigated whether IL-1b-sensitivity is dependent on
the intracellular ICE expression. As expected, in IL-1b-resistant
cancer cell lines, KU-19-19 and KU-19-20, ICE gene expression
was found to be suppressed compared with KU-1 and KU-2 and an
ICE inhibitor YVAD-CHO inhibited IL-1b-induced cell death in
KU-1 and KU-2. These results suggest that ICE inhibition could
cause the resistance to IL-1b.
Furthermore, we showed that both IL-1ra and IL-1ra and IL-1b
antibody, which inhibit IL-1b-IL-1 receptor interaction, blocked
AxIL-1ra-induced cell death in KU-19-19 and KU-19-20. This
result strongly suggests that IL-1b is essential for AxIL-1ra-
induced cell death. We showed pIL-1b to be accumulated in large
quantities in both KU-19-19 and KU-19-20, but not in either KU-
1 or KU-2 by Western blot analysis and that a great deal of IL-1b
was secreted all at once by AxIL-1ra treatment in both KU-19-19
and KU-19-20. Previous works have also demonstrated that mIL-
1b is secreted during apoptosis mediated via a variety of stimuli
(Hogquist et al, 1991; Miura et al, 1993, 1995; Zychlinsky et al,
1994). Friedlander et al (1996) reported that the cleavage and
secretion of endogenous IL-1b plays an important role in ICE-
mediated cell death.
Many authors have recently reported that endogenous IL-1/IL-
1ra balance regulates the homeostasis of cell proliferation and cell
death (Corradi et al, 1995; Furukawa et al, 1995; Goletti et al,
1996; Oelmann et al, 1997). In various types of cells, the produc-
tion and secretion of IL-1 and IL-1ra is simultaneous. In fact, all
the cancer cell lines used in this study express IL-1ra as well as
IL-1b. While IL-1ra is secreted through the classical exocytotic
pathway, IL-1b lacks a secretory signal peptide and its secretion
thus depends on the ICE activity. It is thought to be quite a natural
homeostatic mechanism to block IL-1b secretion in case IL-1ra
expression is suppressed compared with IL-1b expression. While
previous authors referred to the extracellular IL-1/IL-1ra balance,
we have demonstrated that intracellular IL-1b/IL-1ra gene expres-
sion balance plays a crucial role in the cell proliferation and death.
In this study, we demonstrated that the surplus amount of exoge-
nous IL-1ra could promote neither ICE gene expression nor IL-1b
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Figure 7 Measurement of AxIL-1ra-induced apoptosis in KU-19-19 and KU-
19-20 by fragmented DNA ELISA. Cells (1 ´ 104 cells ml–1), treated with AxIL-
1ra (MOI = 5) or AxLacZ (MOI = 5) for different time periods, were transferred
into sterile 1.5-ml microcentrifuge tubes. After cells were then lysed and
centrifuged, 100 ml of tenfold diluted supernatants (1 ´ 103 cell equivalents
ml–1) was pipetted into the 96-well plate and the level of the fragmented DNA
was measured by specific two-site ELISA. In KU-19-19, absorbance was
elevated significantly more in the AxIL-1ra (MOI = 5)-treated cells than in the
AxLacZ (MOI = 5)-treated cells 24 h later and it was dramatically elevated
48 h later (P < 0.01). In KU-19-20, it was also significantly elevated 48 h
later (P < 0.01). The results are expressed as the relative ratio to the
AxLacZ-treated controls. Bars, s.d. of triplicate samples. The experiments
were repeated three times with similar results
Figure 8 Both IL-1b and ICE function are required for AxIL-1ra-induced cell
death in KU-19-19 and KU-19-20. AxIL-1ra (MOI = 5)-infected cells (1 ´ 103
per well) were treated with either IL-1ra (100 ng ml–1), anti-IL-1b antibody
(IL-1b Ab; 10 mg ml–1) or YVAD-CHO (20 mM), and then were incubated for
48 h, and cell survival was estimated by MTT assay. These inhibitors
significantly blocked AxIL-1ra-induced cell death in both KU-19-19 and
KU-19-20 (P < 0.05). IL-1b (10 ng ml–1) could enhance AxIL-1ra-induced
growth inhibition in both KU-19-19 and KU-19-20 (P < 0.05), while it induced
growth promotion under AxLacZ treatment. The results are expressed as the
relative ratio to the AxLacZ-treated controls. Bars, s.d. of triplicate samples.
The experiments were repeated twice with similar resultssecretion in KU-19-19 and KU-19-20, while endogenous IL-1ra
overexpression promotes both ICE gene expression and IL-1b
secretion. Furthermore, Figure 4 shows that AxIL-1ra-induced
ICE gene overexpression occurred earlier than increase of the IL-
1ra concentration in the supernatants in both KU-19-19 and KU-
19-20. We demonstrated that icIL-1ra protein levels were not
different in four cancer cell lines as shown in Figure 1B and
furthermore confirmed that AxIL-1ra did not increase icIL-1ra
protein levels in either KU-19-19 or KU-19-20 (data not shown).
These results strongly support the idea that the regulation of ICE
gene expression is likely due to an intracellular function of sIL-1ra
rather than to either icIL-1ra function or IL-1 receptor-mediated
extracellular event. As far as we investigated, this is a first report
on the intracellular function of sIL-1ra. However, it remains
unclear whether sIL-1ra can directly regulate the level of ICE gene
expression before it is secreted or some other co-factors play a
crucial role in ICE regulation at the transcription level of sIL-1ra,
and the further study will be needed to clarify this mechanism.
It is well known that a 10- to 100-fold molar excess of IL-1ra is
often required to inhibit IL-1 activity (Arend et al, 1990). In the
present study, we found that IL-1ra/IL-1b ratios in the supernatants
were less than 10 in KU-19-19 and KU-19-20, while those were
more than 10 in KU-1 and KU-2. This result suggests that in KU-
19-19 and KU-19-20, IL-1b can overcome IL-1ra at the non-
treated condition. IL-1b is well known as one of the key cytokine
that can promote the production of various cytokines including IL-
6, IL-8, G-CSF and GM-CSF (Dinarello, 1996). Some of these
cytokines might help cell proliferation by an autocrine and/or
paracrine loop (Tachibana et al, 1995) and in fact, high-dose IL-1b
treatment could promote the production of various cytokines and
cell proliferation in both KU-19-19 and KU-19-20. In contrast, IL-
1b treatment blocked cell proliferation in KU-1 and KU-2, and
furthermore it also blocked cell proliferation in AxIL-1ra-treated
KU-19-19 and KU-19-20. Taken together, it is suggested that IL-
1b is associated with both cell proliferation and cell death and that
its function is dependent on the ICE expression. In KU-1 and KU-
2, in which ICE is activated since the endogenous IL-1ra/IL-1b
expression ratio is high, IL-1b functions as an apoptosis inducer.
In contrast, in KU-19-19 and KU-19-20 in which ICE is inhibited
since the endogenous IL-1ra/IL-1b expression ratio is low, IL-1b
can not function as an apoptosis inducer but can promote various
types of cytokine production which thus induce cell proliferation
by an autocrine and/or paracrine loop. Several reports have
referred to this dual function of IL-1b. Fratelli et al (1995) reported
that IL-1b promotes proliferation during the exponential phase,
while it induces apoptosis during the plateau phase of cell growth
in thymoma cells and that a signal exists which converts the
cellular response to IL-1b from proliferation to death.
Furthermore, Friedlander et al (1996) reported that the ICE down-
regulates IL-1b-IL-1 receptor-binding activity, which causes the
resistance to IL-1b. In the preliminary study by receptor-binding
assay, however, we did not find this phenomenon in either KU-19-
19 or KU-19-20 (data not shown).
In conclusion, we demonstrated that the resistance to IL-1b does
not necessarily result from the constitutive IL-1b production but
depends on the level of ICE gene expression, which is regulated by
the level of endogenous sIL-1ra production. Since IL-1b functions
as an inducer of various cytokines which can promote cancer cell
proliferation as indicated in this study, these findings, therefore,
provide key insights into the mechanism underlying the viability
of cancer cells.
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